ClinicalTrials.gg
CompletedNCT01035229EVOLVE-1Updated Sep 22, 2016Results posted

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

A Phase 3 interventional study of Everolimus and Everolimus Placebo in Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 131 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-22.

Primary conditionCarcinoma, HepatocellularRegistry: CarcinomaReclassifiedWhy we changed it
Registry
Carcinoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Hepatocellular
Why
  1. The study's title name Carcinoma, Hepatocellular, a narrower term within Carcinoma.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
546
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Carcinoma, Hepatocellular by Novartis — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Novartis.

Enrollment
Largest of 10
546 · median 98
Started
2010
the only one that year
Phase 3
2 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Carcinoma, Hepatocellular by Novartis, this one has the largest enrollment, is the only one that started in 2010, is one of 2 in phase 3, and was the 4th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 10 studies in Carcinoma, Hepatocellular by Novartis is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Carcinoma, Hepatocellular by Novartis as a file.
02

Study summary

The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant to sorafenib.

03

Conditions studied

  • Carcinoma

Browse trials for

Keywords

  • Hepatocellular carcinoma
  • randomized trial
  • medical treatment
  • RAD001
  • placebo
  • Advanced Hepatocellular Carcinoma (HCC)
04

In context

Carcinoma, Hepatocellular Reclassified

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

This study's enrollment of 546 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Carcinoma, Hepatocellular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Carcinoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced liver cancer
  • Prior systemic treatment with sorafenib for advanced HCC and for whom their disease progressed during or after sorafenib treatment, or were intolerant to sorafenib treatment. Specifically, this can be defined as:

    • Documented radiological confirmation (radiology scans or report) of disease progression during or after sorafenib treatment
    • Intolerance to sorafenib (at any dose and/or duration) is defined as documented sorafenib-related grade 3 or 4 adverse events that led to sorafenib discontinuation.

NOTE:

  • Sorafenib must be the last antineoplastic treatment before randomization
  • Prior local and/or hormonal therapy (e.g., tamoxifen) before sorafenib is allowed
  • One systemic chemotherapy regimen for advanced HCC is allowed before sorafenib treatment

    • performance status of ≤ 2
    • A

Exclusion criteria

Exclusion Criteria:

  • Active bleeding during the last 28 days
  • Prior therapy with mTOR inhibitors
  • Prior liver or other organ transplantation which mandates systemic

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
546 participants (actual)

Study arms

  • Experimental
    Everolimus + Best Supportice Care (BSC)

    Patients were assigned to the Everolimus + BSC arm in a ratio of 2:1 over the Placebo arm. Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the investigational drug. In addition to taking Everolimus, all patients also received BSC as per normal local practice.

    Drug: Everolimus · Other: Best Supportive Care (BSC)

  • Placebo comparator
    Placebo + Best Supportive Care

    Placebo Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the control drug. In addition to taking Placeb Everolimus, all patients also received BSC as per normal local practice.

    Drug: Everolimus Placebo · Other: Best Supportive Care (BSC)

Interventions

  • Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.

    Also known as: RAD001

  • DrugEverolimus Placebo

    Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.

  • OtherBest Supportive Care (BSC)

    BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions

07

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death from any cause. The comparison of OS between the 2 arms was done using a stratified log-rank test at one-sided 2.5% level of significance.

    Time frame: When 454 OS events were observed

Secondary outcomes

  1. Time to Tumor Progression (TTP)

    TTP was defined as the time from the date of randomization to the date of the first documented radiologic confirmation of disease progression. Since the study did not meet the primary objective, TTP was not formally tested.

    Time frame: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient

  2. Percentage of Participants With Disease Control Rate (DCR)

    DCR is defined as the proportion of participants with a best objective response (BOR) of complete response (CR) or partial response (PR) or stable disease (SD) according to RECIST. The BOR was the best response recorded from the start of the treatment until disease progression. CR is disappearance of all target lesions; PR is at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters; SD is neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD is at least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline.

    Time frame: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient

  3. Time to Definitive Deterioration of ECOG Performance Score (PS) Score

    Change in Eastern Cooperative Oncology Group (ECOG) were assessed by time to definitive performance status deterioration by at least one category on the ECOG scale. Deterioration was considered definitive if no improvement in the ECOG PS was observed at a subsequent measurement. ECOG PS: 0=Fully active, able to carry on all pre-disease performance without restriction, 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2=Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4=Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair; 5=Dead

    Time frame: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.

  4. Time to Definitive Deterioration of EORTC QLQ-C30 Scores

    The primary quality of life endpoint was the time to definitive 5% deterioration from baseline in the global health status/quality of life scale of the EORTC QLQ-C30 questionnaire. Definitive deterioration by at least 5% is defined as a decrease in score by at least 5% compared to baseline, with no later observed increase above this threshold. The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the healthrelated quality of life (QoL) of cancer patients participating in international clinical trials. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.

  5. Pharmacokinetics Assessments - Cmin

    Cmin is the pre-dose blood concentration at steady-state (ng/mL). Pre-dose (Cmin) blood samples were collected from all patients in both arms at Visit 3. Steady-state for the Cmin sample was defined as continuous administration of the same dose in the last 4 days prior to the collection of the Cmin sample. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid pre-dose (Cmin) everolimus samples were included in the analysis.

    Time frame: Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.

  6. Pharmacokinetics Assessments - Cmax

    Cmax is the maximum (peak) blood drug concentration after dose administration (ng/mL) calculated as the maximum of C1h and C2h. C1h was 1 hour post-dose blood concentration (ng/mL) and C2h was 2 hour post-dose blood concentration (ng/mL). C1h and C2h post-dose samples were collected from all patients in both arms at Visit 3. Steady-state for the C1h and C2h samples was defined as continuous administration of the same dose in the previous 4 days and the day on which the C1h and C2h samples were collected. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid C1h and C2h everolimus samples were included in the analysis.

    Time frame: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.

08

Results

Posted Oct 27, 2014
Limitations and caveats
Three patients (1 in the everolimus arm and 2 in the placebo arm were excluded from the Safety Set. These three patients were randomized but never received any study treatment.

Participant flow

763 patients screened, 546 randomized. At 14Jun2013 data cut-off (final analysis), 3 pts in everolimus arm, 6 in placebo arm were still on treatment. Of 9 pts, 3 receiving placebo discontinued due to disease progression. Remaining 6 completed study due to sponsor's decision to end study after final results. The LPLV was 15Oct2013.

Participant flow — Overall Study
MilestoneEverolimus + Best Supportive Care (BSC)Placebo + Best Supportive Care
Started362184
Completed00
Not completed362184
Withdrew: Adverse event6114
Withdrew: Withdrawal by subject207
Withdrew: Lost to follow-up10
Withdrew: Administrative problems11
Withdrew: Death135
Withdrew: New cancer therapy20
Withdrew: Protocol violation02
Withdrew: Sponsor's decision to end study33
Withdrew: Disease progression261152

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. The comparison of OS between the 2 arms was done using a stratified log-rank test at one-sided 2.5% level of significance.

Time frame:
When 454 OS events were observed
Reported as:
Median · Months
Overall Survival (OS)
MonthsEverolimus + Best Supportive Care (BSC)Placebo + Best Supportive Care
Overall Survival (OS)7.56 (6.70 to 8.74)7.33 (6.28 to 8.74)
SecondaryTime to Tumor Progression (TTP)

TTP was defined as the time from the date of randomization to the date of the first documented radiologic confirmation of disease progression. Since the study did not meet the primary objective, TTP was not formally tested.

Time frame:
Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient
Reported as:
Median · Months
Time to Tumor Progression (TTP)
MonthsEverolimus + Best Supportive Care (BSC)Placebo + Best Supportive Care
Time to Tumor Progression (TTP)2.96 (2.79 to 4.01)2.60 (1.48 to 2.83)
SecondaryPercentage of Participants With Disease Control Rate (DCR)

DCR is defined as the proportion of participants with a best objective response (BOR) of complete response (CR) or partial response (PR) or stable disease (SD) according to RECIST. The BOR was the best response recorded from the start of the treatment until disease progression. CR is disappearance of all target lesions; PR is at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters; SD is neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD is at least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline.

Time frame:
Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient
Reported as:
Number · Percentage of Participants
Percentage of Participants With Disease Control Rate (DCR)
Percentage of ParticipantsEverolimus + Best Supportive Care (BSC)Placebo + Best Supportive Care
Percentage of Participants With Disease Control Rate (DCR)56.145.1
SecondaryTime to Definitive Deterioration of ECOG Performance Score (PS) Score

Change in Eastern Cooperative Oncology Group (ECOG) were assessed by time to definitive performance status deterioration by at least one category on the ECOG scale. Deterioration was considered definitive if no improvement in the ECOG PS was observed at a subsequent measurement. ECOG PS: 0=Fully active, able to carry on all pre-disease performance without restriction, 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2=Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4=Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair; 5=Dead

Time frame:
Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.
Reported as:
Median · Months
Time to Definitive Deterioration of ECOG Performance Score (PS) Score
MonthsEverolimus + Best Supportive Care (BSC)Placebo + Best Supportive Care
Time to Definitive Deterioration of ECOG Performance Score (PS) Score4.27 (3.32 to 4.86)4.47 (3.02 to 6.08)
SecondaryTime to Definitive Deterioration of EORTC QLQ-C30 Scores

The primary quality of life endpoint was the time to definitive 5% deterioration from baseline in the global health status/quality of life scale of the EORTC QLQ-C30 questionnaire. Definitive deterioration by at least 5% is defined as a decrease in score by at least 5% compared to baseline, with no later observed increase above this threshold. The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the healthrelated quality of life (QoL) of cancer patients participating in international clinical trials. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

Time frame:
Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.
Reported as:
Median · Months
Time to Definitive Deterioration of EORTC QLQ-C30 Scores
MonthsEverolimus + Best Supportive Care (BSC)Placebo + Best Supportive Care
Time to Definitive Deterioration of EORTC QLQ-C30 Scores2.86 (2.66 to 4.11)3.45 (2.79 to 4.17)
SecondaryPharmacokinetics Assessments - Cmin

Cmin is the pre-dose blood concentration at steady-state (ng/mL). Pre-dose (Cmin) blood samples were collected from all patients in both arms at Visit 3. Steady-state for the Cmin sample was defined as continuous administration of the same dose in the last 4 days prior to the collection of the Cmin sample. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid pre-dose (Cmin) everolimus samples were included in the analysis.

Time frame:
Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.
Reported as:
Mean · ng/mL
Pharmacokinetics Assessments - Cmin
ng/mLEverolimus 7.5mg + Best Supportive Care (BSC)Everolimus 5mg + Best Supportive Care (BSC)
Pharmacokinetics Assessments - Cmin16.141 ± 9.22979.318 ± 4.9705
SecondaryPharmacokinetics Assessments - Cmax

Cmax is the maximum (peak) blood drug concentration after dose administration (ng/mL) calculated as the maximum of C1h and C2h. C1h was 1 hour post-dose blood concentration (ng/mL) and C2h was 2 hour post-dose blood concentration (ng/mL). C1h and C2h post-dose samples were collected from all patients in both arms at Visit 3. Steady-state for the C1h and C2h samples was defined as continuous administration of the same dose in the previous 4 days and the day on which the C1h and C2h samples were collected. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid C1h and C2h everolimus samples were included in the analysis.

Time frame:
Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.
Reported as:
Mean · ng/mL
Pharmacokinetics Assessments - Cmax
ng/mLEverolimus 7.5mg + Best Supportive Care (BSC)Everolimus 5mg + Best Supportive Care (BSC)
Pharmacokinetics Assessments - Cmax47.881 ± 21.099931.592 ± 21.1622

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus + Best Supportive Care (BSC)—171/361 (47.4%)343/361 (95%)
Placebo + Best Supportive Care—64/182 (35.2%)147/182 (80.8%)
Most frequent serious events
Showing 10 of 219
Most frequent serious events
EventEverolimus + Best Supportive Care (BSC)Placebo + Best Supportive Care
AscitesGastrointestinal disorders13/36111/182
PneumoniaInfections and infestations18/3611/182
Abdominal painGastrointestinal disorders9/3618/182
AnaemiaBlood and lymphatic system disorders14/3613/182
PyrexiaGeneral disorders14/3612/182
Renal failureRenal and urinary disorders11/3612/182
HyperbilirubinaemiaHepatobiliary disorders5/3615/182
AstheniaGeneral disorders9/3613/182
DyspnoeaRespiratory, thoracic and mediastinal disorders9/3614/182
EpistaxisRespiratory, thoracic and mediastinal disorders9/3610/182
Most frequent other events
Showing 10 of 36
Most frequent other events
EventEverolimus + Best Supportive Care (BSC)Placebo + Best Supportive Care
StomatitisGastrointestinal disorders142/3619/182
Decreased appetiteMetabolism and nutrition disorders114/36127/182
Oedema peripheralGeneral disorders100/36125/182
DiarrhoeaGastrointestinal disorders94/36125/182
FatigueGeneral disorders90/36130/182
PyrexiaGeneral disorders86/36113/182
CoughRespiratory, thoracic and mediastinal disorders79/36123/182
EpistaxisRespiratory, thoracic and mediastinal disorders78/3615/182
RashSkin and subcutaneous tissue disorders76/36116/182
PruritusSkin and subcutaneous tissue disorders64/36129/182

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Everolimus + Best Supportive Care (BSC)Placebo + Best Supportive CareTotal
Mean65.1 ± 11.7064.2 ± 10.4164.8 ± 11.28
Age, Customized
Age, Customized(Participants)Everolimus + Best Supportive Care (BSC)Placebo + Best Supportive CareTotal
< 35 years718
>=35 - <55 years483179
>=55 - <65 years10061161
>= 65 years20791298
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus + Best Supportive Care (BSC)Placebo + Best Supportive CareTotal
Female592483
Male303160463
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus + Best Supportive Care (BSC)Placebo + Best Supportive CareTotal
Caucasian192110302
Black639
Asian13758195
Pacific Islander011
Other271239
Weight
Weight(kg)Everolimus + Best Supportive Care (BSC)Placebo + Best Supportive CareTotal
Mean69.6 ± 15.6271.3 ± 17.7170.2 ± 16.35
Height
Height(cm)Everolimus + Best Supportive Care (BSC)Placebo + Best Supportive CareTotal
Mean167.9 ± 8.66169.2 ± 8.84168.3 ± 8.73
BMI
BMI(kg/m^2)Everolimus + Best Supportive Care (BSC)Placebo + Best Supportive CareTotal
Mean24.5 ± 4.6424.8 ± 4.9924.6 ± 4.76
09

Study locations

131 sites
  • Highlands Oncology Group Dept of Highlands Oncology Grp
    Fayetteville, Arkansas 72703, United States
  • Compassionate Cancer Care Medical Group CCCMG
    Fountain Valley, California 92708, United States
  • University of California San Diego - Moores Cancer Center SC - 3
    La Jolla, California 92093-0658, United States
  • California Pacific Medical Center California Pacific Med
    San Francisco, California 94120-7999, United States
  • Rocky Mountain Cancer Centers RMCC - Denver-Midtown (4)
    Greenwood Village, Colorado, United States
  • Queen's Medical Center Queens Cancer Center
    Honolulu, Hawaii 96817, United States
  • The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Dept. of SKCC @ JHU
    Baltimore, Maryland 21287-0013, United States
  • Massachusetts General Hospital Dept. of Mass General Hospital
    Boston, Massachusetts 02114, United States
  • Midwest Cancer Care Physicians Research Medical Center
    Kansas City, Missouri 64131, United States
  • VA Sierra Nevada Health Care System Dept. of VA Sierra Nevada HCS
    Reno, Nevada 89502, United States
  • University of Rochester Medical Center Rochester
    Rochester, New York 14642, United States
  • Northwest Cancer Specialists Rose Quarter Cancer Center
    Portland, Oregon 97210, United States
  • St. Luke's Hospital and Health Network St. Luke's Cancer Network (2)
    Bethlehem, Pennsylvania, United States
  • Texas Cancer Center - Abilene
    Abilene, Texas 79606, United States
  • Methodist Charlton Cancer Center Methodist
    Dallas, Texas 75237, United States
  • University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(3)
    Dallas, Texas 75390-8527, United States
  • Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio
    San Antonio, Texas 78229, United States
  • Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care
    Roanoke, Virginia 24018, United States
  • University of Washington Cancer Care SC
    Seattle, Washington 98109-1023, United States
  • Novartis Investigative Site
    Camperdown, New South Wales 2050, Australia
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Innsbruck, A-6020, Austria
  • Novartis Investigative Site
    Wien, 1090, Austria
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Edegem, 2650, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    London, Ontario N6A 4L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M4N 3M5, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2X 1P1, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3A 1A1, Canada
  • Novartis Investigative Site
    Nanjing, Jiangsu 210002, China
  • Novartis Investigative Site
    Xi'an, Shanxi 710032, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310016, China
  • Novartis Investigative Site
    Beijing, 100039, China
  • Novartis Investigative Site
    Guangzhou, 510060, China
  • Novartis Investigative Site
    Amiens cedex 1, 80054, France
  • Novartis Investigative Site
    Avignon Cedex, 84082, France
  • Novartis Investigative Site
    Bordeaux Cedex, 33075, France
  • Novartis Investigative Site
    Caen Cedex9, 14033, France
  • Novartis Investigative Site
    Chambray-lès-Tours, 37170, France
  • Novartis Investigative Site
    Clermont Ferrand cedex 1, 63003, France
  • Novartis Investigative Site
    Clichy, 92110, France
  • Novartis Investigative Site
    Dijon, 21079, France
  • Novartis Investigative Site
    Lille Cedex, 59037, France
  • Novartis Investigative Site
    Lyon Cedex 04, 69317, France
  • Novartis Investigative Site
    Marseille Cédex 5, 13385, France
  • Novartis Investigative Site
    Montpellier Cedex 5, 34298, France
  • Novartis Investigative Site
    Nantes Cedex 1, 44093, France
  • Novartis Investigative Site
    Nice Cedex 3, 06202, France
  • Novartis Investigative Site
    Reims, 51092, France
  • Novartis Investigative Site
    Rouen Cedex, 76031, France
  • Novartis Investigative Site
    St Priest en Jarez Cedex, 42277, France
  • Novartis Investigative Site
    Strasbourg, 67091, France
  • Novartis Investigative Site
    Mannheim, Baden-Württemberg 68305, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Esslingen, 73730, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Goettingen, D-37075, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Würzburg, 97080, Germany
  • Novartis Investigative Site
    Athens, GR 124 62, Greece
  • Novartis Investigative Site
    Larissa, GR 411 10, Greece
  • Novartis Investigative Site
    Thessaloniki, 57001, Greece
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Budapest, H-1122, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Szeged, H-6720, Hungary
  • Novartis Investigative Site
    Szombathely, 9700, Hungary
  • Novartis Investigative Site
    Petach Tikva, 49100, Israel
  • Novartis Investigative Site
    Ramat Gan, 5266202, Israel
  • Novartis Investigative Site
    Benevento, BN 82100, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Foggia, FG 71100, Italy
  • Novartis Investigative Site
    Milano, MI 20122, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Modena, MO 41100, Italy
  • Novartis Investigative Site
    Palermo, PA 90127, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Aviano, PN 33081, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Roma, RM 00128, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Frattamaggiore, 80020, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
  • Novartis Investigative Site
    Nagoya, Aichi 464-8681, Japan
  • Novartis Investigative Site
    Chiba-city, Chiba 260-8677, Japan
  • Novartis Investigative Site
    Kashiwa, Chiba 277-8577, Japan
  • Novartis Investigative Site
    Matsuyama, Ehime 791-0280, Japan
  • Novartis Investigative Site
    Iizuka-city, Fukuoka 820-8505, Japan
  • Novartis Investigative Site
    Gifu-shi, Gifu 500-8513, Japan

Showing the first 100 of 131 sites across 18 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Zhu AX, Chen D, He W, Kanai M, Voi M, Chen LT, Daniele B, Furuse J, Kang YK, Poon RT, Vogel A, Chiang DY. Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. J Hepatol. 2016 Aug;65(2):296-304. doi: 10.1016/j.jhep.2016.04.015. Epub 2016 Apr 27. PubMed 27130844 ↗
  • Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014 Jul 2;312(1):57-67. doi: 10.1001/jama.2014.7189. PubMed 25058218 ↗

Related links

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2009
First posted
Dec 18, 2009
Start
Apr 2010
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Oct 27, 2014
Last update
Sep 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01035229
Responsible party
Sponsor
First posted
Dec 18, 2009
Start date
Apr 2010
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Oct 27, 2014
Last update
Sep 22, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion